簡(jiǎn)要描述:
YY1185RAnti-TrK A.B.C(Tyrosine kinase,TrkA.B.C)酪氨酸激酶A.B.C抗體50ug/100ug
更新時(shí)間:2024-08-18;廠商性質(zhì):經(jīng)銷(xiāo)商;覽量:483
YY1185R Anti-TrK A.B.C(Tyrosine kinase,TrkA.B.C)酪氨酸激酶A.B.C抗體 50ug/100ug
YY0109M Anti-Leptin receptor(long) 瘦素受體抗體(長(zhǎng)) 50ug/100ug
YY0109R Anti-Leptin receptor(long) 瘦素受體抗體(長(zhǎng)) 50ug/100ug
YY1117R Anti-Lgr5/GPR49 腸上皮干細(xì)胞蛋白抗體 50ug/100ug
RCt-0506M Anti-LH (Mouse Anti-Human Luteinizing Hormone Monoclonal Antibody) 鼠抗人促黃體生成素抗體 50ug/100ug
YY1054R Anti-L-HDC (L-Histidine decarboxylase) L-組氨酸脫羧酶抗體 hu, mo, rat, bov, dog, pig, chi 50ug/100ug
YY0456R Anti-LHRH/GNRH (luteinizing hormone-releasing hormone) 黃體激素釋放激素抗體/促性腺激素釋放激素抗體 50ug/100ug
YY1058R Anti-LIF (leukemia inhibitory factor) 白血病抑制因子抗體 50ug/100ug
YY1177R Anti-Lingo-1 Nogo受體作用蛋白抗體 50ug/100ug
YY0738R Anti-Livin (Inhibitors of apoptosis proterins Livin) 一種新的凋亡抑制蛋白抗體 50ug/100ug
YY0824R anti-LFABP/FABP-1(Liver Fatty acid binding protein) 肝臟型脂肪酸結(jié)合蛋白抗體 50ug/100ug
YY1185R Anti-TrK A.B.C(Tyrosine kinase,TrkA.B.C)酪氨酸激酶A.B.C抗體 50ug/100ug
YY0897R anti-LFABP/FABP-1(Liver Fatty acid binding protein) 肝臟型脂肪酸結(jié)合蛋白抗體 50ug/100ug
YY0821R Anti-LN (laminin) 層粘連蛋白抗體 50ug/100ug
YY0759R Anti-Lpin1 protein Lpin1 抗體 50ug/100ug
YY0760R Anti-Lpin1 protein Lpin1 抗體 50ug/100ug
YY0661R Anti-LRP/MVP (Lung resistance related protein) 肺耐藥相關(guān)蛋白抗體 50ug/100ug
YY0683R Anti-LRRK2 (Leucine-rich repeat kinase 2) 帕金森氏病致病基因/神經(jīng)系統(tǒng)新功能基因抗體 50ug/100ug
YY0484R Anti-Lumbrokinase 抗蚯蚓纖溶酶抗體/抗蚓激酶抗體 50ug/100ug
YY0816R Anti-Lysozyme 溶菌酶抗體 50ug/100ug
YY1311R anti-LYVE-1(lymphalic vessel endotheilial hyaluronan receptor 1) 淋巴管內(nèi)皮透明質(zhì)酸受體抗體 50ug/100ug
YY0101R Anti-M2-PK ( pyruvate Kinase M2) 丙酮酸激酶-M2抗體 50ug/100ug
YY1185R Anti-TrK A.B.C(Tyrosine kinase,TrkA.B.C)酪氨酸激酶A.B.C抗體 50ug/100ug
MBL
成立于1969年,是日本*家抗體商。公司早期致力于研究血漿蛋白質(zhì)抗體,是抗體研究、發(fā)展和的先鋒者?,F(xiàn)在,公司提供3000多種細(xì)胞骨架、致癌基因產(chǎn)品和信號(hào)轉(zhuǎn)導(dǎo)蛋白質(zhì)抗體。1975年,MBL成為日本血漿蛋白質(zhì)的診斷劑的商,之后,公司就致力于開(kāi)發(fā)、免疫診斷試劑,特別是自身免疫性疾病方面的診斷試劑。公司的能力在該領(lǐng)域中得到了*的評(píng)價(jià)。MBL的自身免疫性疾病的診斷劑對(duì)醫(yī)藥界貢獻(xiàn)非常大,該公司產(chǎn)品在自身免疫性疾病方面占據(jù)了日本國(guó)內(nèi)市場(chǎng)80%的份額,在海外市場(chǎng)也同樣受到歡迎。近年來(lái),MBL大力引進(jìn)重組DNA細(xì)胞和細(xì)胞融合技術(shù)來(lái)開(kāi)發(fā)用于疾病診斷和療效觀察的診斷試劑。另外,公司開(kāi)發(fā)了大量分子生物學(xué)和細(xì)胞生物學(xué)研究的產(chǎn)品,包括抗體和可溶性Fas ELISA試劑盒。
YY1185R Anti-TrK A.B.C(Tyrosine kinase,TrkA.B.C)酪氨酸激酶A.B.C抗體 50ug/100ug